Collegium Reports Q3 2026 Results; Reaffirms Full-Year 2026 Guidance
Collegium Pharmaceutical reported a record $216.3 million in quarterly net revenues, fueled by a 24% year-over-year increase in JORNAY PM sales. The company also reiterated its 2026 financial outlook and announced a $50 million share repurchase program to deploy capital into shareholder value.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed